THERACRYF PLC (TCF) — Half Year Results

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and welcome to the THERACRYF Half Year Results Investor Presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged. They can be submitted at any time. Please just use the Q and A tab on the right hand corner of your screen to be typing your questions and press send. The company may not be in a position to answer every question it receives during today's meeting. However, the company can review your questions submitted today, we'll publish those responses where it's appropriate to do so. Before we begin, we'd like to submit the following poll, and I'm sure the company be most grateful for your participation. I'd now like to hand over today's management team, Tony Hugh. Good morning. Thanks, Mark. Good morning, everybody, and thanks for attending our half year results presentation. I wanna start by paying tribute to our late chair, doctor Sue Foden. Sue had a profound effect on many people in our biotech industry, and we send our deepest condolences and sympathies to her family. She passed away at the beginning of this month. But as Sue would say, now then let's get on with business, and that's what we're gonna do. So we're gonna take you through the r and s that was issued this morning in a bit more detail, and we'll deal with as many questions as we can. And thank you for those questions who have already been submitted. And we're a public company listed on AIM, as you know, and the usual disclaimers apply. So now then let's remind everybody of what we're about. We're on a mission to build a drug development powerhouse. And where we see this is where's appropriate for a small biotech to act, where those profitable segments We have to segment somewhere, and our segments that w...